RT Journal Article
T1 Comorbidity management in spondyloarthritis
A1 López-Medina, Clementina
A1 Molto, Anna
K1 Spondylitis, ankylosing
K1 Bone density
K1 Cardiovascular diseases
K1 Spondylitis
K1 Comorbidity
K1 Espondilitis anquilosante
K1 Densidad ósea
K1 Enfermedades cardiovasculares
K1 Espondilitis
K1 Comorbilidad
AB Comorbidities are defined as coexistent clinical disorders that appear as a consequence of persistent inflammatory activity and/or treatment. Comorbidities in spondyloarthritis (SpA) are frequent, contributing to a poorer quality of life, higher mortality and incremented healthcare costs. Several recommendations for the screening and management of these comorbidities have been developed in recent years with the aim of improving the different outcomes in these patients. Osteoporosis is the most prevalent comorbidity in patients with SpA, mainly caused by systemic inflammation and a lack of mobility, while cardiovascular diseases explain the increased mortality in patients with SpA with regard to the general population. Data from randomised controlled trials show a low incidence of infections in both patients with and without immunosuppressive treatment, and no evidence of a high incidence of malignant diseases has been demonstrated in these patients. Finally, concomitant fibromyalgia deserves attention, since its coexistence with SpA leads to a poorer treatment response and more switches of anti-TNF treatments. In this review, we show an update of the most common comorbidities in patients with SpA, and we discuss the latest evidence on the management of such comorbidities.
PB BMJ
YR 2020
FD 2020-09-05
LK http://hdl.handle.net/10668/3835
UL http://hdl.handle.net/10668/3835
LA en
NO López-Medina C, Molto A. Comorbidity management in spondyloarthritis. RMD Open. 2020 Sep;6(2):e001135
DS RISalud
RD Apr 19, 2025